Novartis’s Iptacopan Pulls Ahead In Race To Fill Nephrology Unmet Need
Phase II Trial In Rare Kidney Disease Is A Success
The first-in-class candidate met two primary endpoints in a Phase II trial for C3 glomerulopathy, suggesting potential edge over ChemoCentryx and Vifor’s competitor avacopan.
You may also be interested in...
"We are definitely worried," Tschudin said about some US drug price reform proposals. She also spoke with Scrip about competitive rebating and new growth opportunities for anchor brands.
First-in-class iptacopan could help Novartis expand into kidney disease, and take on Alexion’s blockbuster rare disease franchise.
The company’s lead candidate, AP1189, has shown promise in a mid-stage rheumatoid arthritis study, sparking plans for an imminent strategic business collaboration.